SAN FRANCISCO, July 9 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that it has appointed Sarvajit Chakravarty, Ph.D., as vice president of medicinal chemistry. Dr. Chakravarty is responsible for all of the Company’s medicinal chemistry work, including the development of second generation analogs of Medivation’s proprietary small molecule Dimebon(TM).
“The strong efficacy and safety data that Dimebon has shown to date in Alzheimer’s disease makes the development of second generation molecules an extremely important corporate objective,” said David Hung, M.D., president and chief executive officer of Medivation. “Jit has been leading our Dimebon analog program since 2006, and given the importance of this program we believe that it is the right time to bring him on board as a full-time employee.”
Dr. Chakravarty held medicinal chemistry positions of increasing seniority at Scios, Inc. from 1992 to 2006, serving most recently as Director of Medicinal Chemistry, where he managed the medicinal chemistry group. While at Scios, Dr. Chakravarty played a significant role in the discovery and development of novel kinase inhibitors, most notably the clinical candidate, SCIO-469.
Dr. Chakravarty holds a bachelors degree in Chemistry from St. Stephen’s College, Delhi University, and a Ph.D. in organic chemistry from New York University. He is an author on more than 30 scientific publications and an inventor on more than 15 issued patents.
About Medivation
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation’s current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer’s disease, Huntington’s disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company’s product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company’s financial and operating results.
Medivation, Inc.
CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,+1-415-543-3470, x201; or Jani Bergan of WeissComm Partners,+1-415-946-1064
Web site: http://www.medivation.com/
